Treatment failure, death, and predictors among PLWHIV on second-line antiretroviral therapy in Dessie Comprehensive Specialized Hospital, northeast Ethiopia: A retrospective cohort study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
08
2021
accepted:
17
05
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
The proportion of HIV patients on second-line antiretroviral therapy is becoming a growing public health concern, especially in a low-income country setting. However, unlike first-line therapy, to date, very little is known about the outcomes of second-line therapy in the Ethiopia context. Thus, this study was conducted to determine the rate of treatment failure, death, and their predictors among HIV patients receiving second-line therapy. A retrospective cohort study was conducted on 642 people living with HIV in Dessie Comprehensive Specialized Hospital from October 2016 to November 2019. Poisson and competitive risk survival models were computed to explore predictors of treatment failure and death, respectively. During follow-up period, 39 (6.87%, 95% CI: 5-9.2%) of 568 patients had second-line treatment failure with 4.07 per 100 person-year rate of failure. Being on anti-TB treatment [Rate ratio, RR = 2.57 (95% CI: 1.25-5.25)], not having optimal medication adherence [RR = 2.29 (95% CI: 1.09-4.78)], and not timely switched [RR = 5.89 (95% CI: 1.36-25.54)] were positively associated with treatment failure. Similarly, 44 (6.85%, 95% CI: 5-9%) of 642 patients died with 4.5 per 100 person-year rate of death. Being on advanced clinical condition [Sub distribution Hazard ratio, SHR = 2.49 (95% CI: 1.31-4.74)], not having optimal medication adherence [SHR = 2.65 (95% CI: 1.31-4.74)], lower CD4 cell counts, and high viral load measurement were positively associated with death. A significant number of patients had failed to respond to second-line therapy. A large number of patients had also died. Patient medical profile and monitoring practice were associated with treatment failure and death. Hence, patient-centered monitoring and interventions should be strengthened, besides treatment switch.
Sections du résumé
BACKGROUND
The proportion of HIV patients on second-line antiretroviral therapy is becoming a growing public health concern, especially in a low-income country setting. However, unlike first-line therapy, to date, very little is known about the outcomes of second-line therapy in the Ethiopia context. Thus, this study was conducted to determine the rate of treatment failure, death, and their predictors among HIV patients receiving second-line therapy.
METHODS
A retrospective cohort study was conducted on 642 people living with HIV in Dessie Comprehensive Specialized Hospital from October 2016 to November 2019. Poisson and competitive risk survival models were computed to explore predictors of treatment failure and death, respectively.
RESULTS
During follow-up period, 39 (6.87%, 95% CI: 5-9.2%) of 568 patients had second-line treatment failure with 4.07 per 100 person-year rate of failure. Being on anti-TB treatment [Rate ratio, RR = 2.57 (95% CI: 1.25-5.25)], not having optimal medication adherence [RR = 2.29 (95% CI: 1.09-4.78)], and not timely switched [RR = 5.89 (95% CI: 1.36-25.54)] were positively associated with treatment failure. Similarly, 44 (6.85%, 95% CI: 5-9%) of 642 patients died with 4.5 per 100 person-year rate of death. Being on advanced clinical condition [Sub distribution Hazard ratio, SHR = 2.49 (95% CI: 1.31-4.74)], not having optimal medication adherence [SHR = 2.65 (95% CI: 1.31-4.74)], lower CD4 cell counts, and high viral load measurement were positively associated with death.
CONCLUSIONS
A significant number of patients had failed to respond to second-line therapy. A large number of patients had also died. Patient medical profile and monitoring practice were associated with treatment failure and death. Hence, patient-centered monitoring and interventions should be strengthened, besides treatment switch.
Identifiants
pubmed: 35648771
doi: 10.1371/journal.pone.0269235
pii: PONE-D-21-27194
pmc: PMC9159605
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0269235Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
AIDS. 2021 Jun 1;35(7):1103-1112
pubmed: 33534204
AIDS Res Treat. 2017;2017:5415298
pubmed: 29214077
Clin Infect Dis. 2009 Jan 1;48(1):115-122
pubmed: 20380075
AIDS Res Ther. 2021 Apr 21;18(1):17
pubmed: 33882938
Trop Med Int Health. 2016 Sep;21(9):1131-7
pubmed: 27383454
Afr Health Sci. 2020 Mar;20(1):91-101
pubmed: 33402897
Lancet HIV. 2017 Oct;4(10):e433-e441
pubmed: 28784426
Clin Infect Dis. 2015 Jul 1;61(1):95-101
pubmed: 25838288
Pan Afr Med J. 2019 Jun 06;33:89
pubmed: 31489067
AIDS Res Hum Retroviruses. 2017 Dec;33(12):1181-1184
pubmed: 28793781
BMC Infect Dis. 2015 Nov 14;15:517
pubmed: 26572102
Sci Rep. 2020 May 26;10(1):8699
pubmed: 32457309
BMC Infect Dis. 2019 Jul 9;19(1):599
pubmed: 31288748
PLoS One. 2019 Jul 29;14(7):e0220159
pubmed: 31356613
AIDS. 2008 Jul 11;22(11):1305-12
pubmed: 18580610
J Infect Dis. 2008 May 15;197 Suppl 3:S272-8
pubmed: 18447613
Lancet HIV. 2016 Mar;3(3):e132-9
pubmed: 26939736
AIDS. 2014 Sep 10;28(14):2097-107
pubmed: 24977440
HIV AIDS (Auckl). 2020 Jul 30;12:307-314
pubmed: 32801929
Medicine (Baltimore). 2015 Oct;94(43):e1715
pubmed: 26512561
BMJ Open. 2016 Dec 8;6(12):e012537
pubmed: 27932339
BMC Public Health. 2020 Jan 20;20(1):82
pubmed: 31959136
J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):74-8
pubmed: 23774877
Drug Saf. 2018 Dec;41(12):1343-1353
pubmed: 30043384
PLoS One. 2020 Sep 28;15(9):e0239191
pubmed: 32986756